xpertsystems/hconc006-sample

HC-ONC-006 — 肝癌（HCC）合成队列样本数据集，来自XpertSystems.ai合成数据工厂—肿瘤学垂直领域，SKU 6。这是一个完全合成的肝细胞癌（HCC）队列，涵盖完整的临床路径：肝硬化病因分层（HBV/HCV/ALD/NASH/隐源性）、全面的肝脏储备评估（Child-Pugh A/B/C、MELD、MELD-Na、腹水等级、肝性脑病、门脉高压、静脉曲张、PVT）、BCLC分期（0/A/B/C/D）及肿瘤负荷细节（数量、最大直径、直径总和、Milan + UCSF标准、大血管侵犯、肝外扩散、卫星结节、破裂、双叶分布）、AFP/AFP-L3/DCP（PIVKA-II）生物标志物面板（含反应/进展标志和倍增时间）、全面的分子谱分析（TERT启动子突变、CTNNB1、TP53、ARID1A、MET扩增、FGF19、CDKN2A、PD-L1 TPS+CPS、TMB、组织学分级、Wnt通路）、局部区域治疗（TACE-DEB/常规、TARE-Y90剂量学、RFA/MWA/PEI/冷冻消融及mRECIST反应、降期、桥接治疗）、肝移植评估（Milan/UCSF/降期/Metroticket标准、MELD例外、等待名单、供体类型LDLT/DDLT、缺血时间、移植后结果包括复发部位和时间、排斥、免疫抑制）、手术切除（开放/腹腔镜/机器人、R状态、未来肝残余、术中失血、Pringle手法、手术时间、肝切除术后肝衰竭、胆漏、住院时间、无复发生存）、IMbrave150/HIMALAYA时代系统治疗（Atezolizumab+Bevacizumab、Durvalumab+Tremelimumab、Sorafenib、Lenvatinib、Durvalumab；二线Cabozantinib/Regorafenib/Ramucirumab/Pembrolizumab）及RECIST反应、基于关键试验校准的PFS/OS、全面毒性分析（索拉非尼HFSR、贝伐珠单抗HTN/出血、irAE类型和等级、乐伐替尼剂量减少）、生存终点、生活质量（FACT-Hep、EQ-5D），以及一个按OS截断的季度AFP+DCP纵向面板。数据集旨在直接用于分析、建模、演示和教育，同时保持100%合成—无真实患者数据、无PHI、无重新识别风险。HC-ONC-006 — Liver Cancer (HCC) Synthetic Cohort sample dataset from the XpertSystems.ai Synthetic Data Factory — Oncology vertical, SKU 6. A fully synthetic hepatocellular carcinoma (HCC) cohort spanning the complete clinical pathway: cirrhosis etiology stratification (HBV/HCV/ALD/NASH/Cryptogenic), comprehensive hepatic reserve assessment (Child-Pugh A/B/C, MELD, MELD-Na, ascites grade, encephalopathy, portal hypertension, varices, PVT), BCLC staging (0/A/B/C/D) with tumor burden detail (count, largest diameter, sum of diameters, Milan + UCSF criteria, macrovascular invasion, extrahepatic spread, satellite nodules, rupture, bilobar distribution), AFP / AFP-L3 / DCP (PIVKA-II) biomarker panel with response/progression flags and doubling time, comprehensive molecular profiling (TERT promoter mutations, CTNNB1, TP53, ARID1A, MET amplification, FGF19, CDKN2A, PD-L1 TPS+CPS, TMB, histologic grade, Wnt pathway), locoregional therapy (TACE-DEB/conventional, TARE-Y90 with dosimetry, RFA/MWA/PEI/Cryoablation with mRECIST response, downstaging, bridge therapy), liver transplant evaluation (Milan/UCSF/Downstaged/Metroticket criteria, MELD exception, waitlist, donor type LDLT/DDLT, ischemia times, post-transplant outcomes including recurrence with site and timing, rejection, immunosuppression), surgical resection (Open/Laparoscopic/Robotic, R-status, FLR, EBL, Pringle, operative time, post-hepatectomy liver failure, bile leak, LOS, RFS), IMbrave150/HIMALAYA-era systemic therapy (Atezolizumab+Bevacizumab, Durvalumab+Tremelimumab, Sorafenib, Lenvatinib, Durvalumab; second-line Cabozantinib/Regorafenib/Ramucirumab/Pembrolizumab) with RECIST response, PFS/OS by regimen calibrated to landmark trials, comprehensive toxicity profiling (sorafenib HFSR, bevacizumab HTN/bleeding, irAE type and grade, lenvatinib dose reduction), survival endpoints, QoL (FACT-Hep, EQ-5D), and a quarterly AFP+DCP longitudinal panel truncated by OS. Built to be drop-in usable for analytics, modeling, demos, and education while remaining 100% synthetic — no real patient data, no PHI, no re-identification risk.